In This Article:
What Happened?
A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%, while the baseline 10% tariffs remained in place for most countries. This added layer of uncertainty reminded investors that the global trade environment remained volatile, limiting the potential for sustained market gains.
Also President Trump indicated he was willing to accept pain in the short term, and was aware his policies could cause a recession, but he remained more mindful of a more severe case of economic depression (higher unemployment and prolonged downturn).
For investors, this suggested that the administration could prioritize long-term structural shifts over near-term economic stability, further increasing policy-driven risk in the markets.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, following stocks were impacted:
-
Surgical Equipment & Consumables - Diversified company BD (NYSE:BDX) fell 6.2%. Is now the time to buy BD? Access our full analysis report here, it’s free.
-
Surgical Equipment & Consumables - Specialty company Teleflex (NYSE:TFX) fell 6.1%. Is now the time to buy Teleflex? Access our full analysis report here, it’s free.
-
Patient Monitoring company Insulet (NASDAQ:PODD) fell 6.2%. Is now the time to buy Insulet? Access our full analysis report here, it’s free.
-
Drug Development Inputs & Services company UFP Technologies (NASDAQ:UFPT) fell 7.3%. Is now the time to buy UFP Technologies? Access our full analysis report here, it’s free.
-
Medical Devices & Supplies - Specialty company Haemonetics (NYSE:HAE) fell 7.3%. Is now the time to buy Haemonetics? Access our full analysis report here, it’s free.
Zooming In On Haemonetics (HAE)
Haemonetics’s shares are not very volatile and have only had 6 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
Haemonetics is down 26.3% since the beginning of the year, and at $57.79 per share, it is trading 40.6% below its 52-week high of $97.37 from May 2024. Investors who bought $1,000 worth of Haemonetics’s shares 5 years ago would now be looking at an investment worth $589.45.
Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.